公开(公告)号：EP3140282B1

公开(公告)日：2019-07-10

申请号：EP15790006.9

申请日：2015-05-06

申请人： The Johns Hopkins University ,  Northwestern University

发明人： RAY, Sangeeta ,  POMPER, Martin G. ,  MEADE, Thomas J. ,  MEASE, Ronnie C. ,  CHEN, Ying ,  YANG, Xing ,  ROTZ, Matthew

IPC分类号： A61K49/10 ,  A61K49/12 ,  A61K51/04 ,  A61K51/06 ,  A61P35/00 ,  A61K103/00 ,  A61K103/20 ,  A61K103/30 ,  A61K103/32 ,  C07D403/14 ,  C07D257/02

公开(公告)号：EP3140282A1

公开(公告)日：2017-03-15

申请号：EP15790006.9

申请日：2015-05-06

申请人： The Johns Hopkins University ,  Northwestern University

发明人： RAY, Sangeeta ,  POMPER, Martin G. ,  MEADE, Thomas J. ,  MEASE, Ronnie C. ,  CHEN, Ying ,  YANG, Xing ,  ROTZ, Matthew

IPC分类号： C07C233/36 ,  C07C233/05 ,  A61K49/06 ,  A61K49/10

CPC分类号： C07D257/02 ,  A61K49/0002 ,  A61K49/106 ,  A61K49/12 ,  A61K51/0482 ,  A61K51/0497 ,  A61K51/06 ,  C07D403/14

摘要： Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific Ti contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.

摘要翻译： 公开了用于PSMA特异性Ti加权MR成像的低分子量钆（Gd）基MR造影剂。 （Gd）基MR造影剂显示出对PSMA的高结合亲和力，并且在PSMA +细胞中表现出特定的Ti对比度增强。 PSMA靶向的基于Gd的MR造影剂可用于体内PSMA靶向成像。 还提供86Y标记的PSMA结合脲，其中PSMA结合脲也适用于其它放射治疗剂。

公开(公告)号：EP3536345A1

公开(公告)日：2019-09-11

申请号：EP19169083.3

申请日：2015-05-06

申请人： The Johns Hopkins University ,  Northwestern University

发明人： RAY, Sangeeta ,  POMPER, Martin G. ,  MEADE, Thomas J. ,  MEASE, Ronnie C ,  CHEN, Ying ,  YANG, Xing ,  ROTZ, Matthew

IPC分类号： A61K51/04 ,  A61K49/00 ,  A61K49/10 ,  A61P35/00 ,  A61K49/12 ,  A61K51/06 ,  C07D257/02 ,  C07D403/14 ,  A61K103/00 ,  A61K103/20 ,  A61K103/30 ,  A61K103/32

摘要： Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific T 1 contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86 Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.